Inovio gets second grant to fund bioterrorism synthetic vaccines

Inovio Pharmaceuticals (AMEX:INO) received a second grant by the U.S. Defence Department to fund bioterrorism synthetic vaccines program, the company said Monday.

The grant allows Inovio to advance development of a low-cost, non-invasive surface electroporation delivery device and test its utility with its novel synthetic DNA-based vaccines against viruses with a bioterrorism potential, including hanta, puumala,
arenavirus and pandemic influenza.

Good may come of the bioterror hype yet!

Via www.proactiveinvestors.com

This entry was posted on 3 April, 2012 at 09:26 and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

ViroBlogy